STAGE IV LUNG CANCER AJCC V8

This early-phase study tests a personalized vaccine made from unique markers on a patient's own tumor. The goal is to help the immune system fight advanced breast cancer, melanoma, and lung cancer that has not responded to other treatments. About 25 adults with these cancers will…

This study tests whether adding chemotherapy to immunotherapy works better than immunotherapy alone for adults aged 70 and older with advanced non-small cell lung cancer. About 304 participants will receive either pembrolizumab alone or pembrolizumab plus chemotherapy. The goal i…

This study compares two types of radiation for people with small cell lung cancer that has spread to the brain. One method uses a precise, high-dose beam to each tumor, while the other treats the whole brain but avoids the memory center. The goal is to see which approach better p…

This study tests whether a precise type of radiation to the brain and spinal cord can control cancer that has spread to the fluid around the brain, while protecting a memory-related area called the hippocampus. About 22 adults with breast or lung cancer that has spread to the bra…

This study is for people with stage IV or returning non-small cell lung cancer who have already tried chemotherapy and immunotherapy. It compares the usual two-drug treatment (docetaxel and ramucirumab) against the same two drugs plus a third drug called cemiplimab, which helps t…

This early-phase study tests two drugs, osimertinib and tegavivint, as the first treatment for people with a specific type of advanced lung cancer (EGFR-mutant NSCLC) that has spread. The main goal is to find the safest and most effective dose. About 24 adults with this cancer wi…

This study tests a drug called avapritinib in people with advanced solid tumors that have certain genetic changes (CKIT or PDGFRA mutations). The goal is to see if the drug can shrink or control the cancer. About 50 adults with cancers like melanoma, sarcoma, or breast, lung, or …

This early-stage trial is testing whether combining vismodegib (a drug that blocks cancer cell growth) with atezolizumab (an immunotherapy that helps the immune system attack cancer) is safe and tolerable for people with advanced non-small cell lung cancer that has returned or sp…

This study tests a combination of chemotherapy (temozolomide) and immunotherapy (atezolizumab) in people with small cell lung cancer that has spread or returned after initial treatment. The goal is to see if this combo can shrink tumors and help patients live longer. About 56 adu…

This study tests whether adding ramucirumab to tepotinib works better than tepotinib alone for people with a specific type of advanced lung cancer (MET exon 14 skipping). Tepotinib blocks a faulty protein that makes cancer cells grow, while ramucirumab cuts off the tumor's blood …

This early-stage trial tests a new drug (MRX-2843) combined with a standard targeted therapy (osimertinib) for people with advanced EGFR-mutant non-small cell lung cancer. The goal is to find the safest dose and see how well the combination works. About 69 participants will be en…

This study tests whether adding an experimental drug (GT103) to an existing immunotherapy (pembrolizumab) can help people with a specific type of advanced lung cancer (STK11 mutant NSCLC) that has stopped responding to treatment. About 28 adults whose cancer has spread will recei…

This study tests a personalized vaccine made from a patient's own tumor proteins, combined with the immunotherapy drug pembrolizumab, for people with advanced solid tumors. The goal is to see if this combination is safe and helps the immune system attack cancer more effectively. …

This study tests whether adding diclofenac, a common anti-inflammatory painkiller, can help control tumor growth in people with advanced non-small cell lung cancer whose disease is starting to worsen while on immunotherapy alone. About 20 adults with stage III or IV lung cancer w…

This study tests whether adding bevacizumab to the standard drug osimertinib helps people with advanced EGFR-mutant non-small cell lung cancer live longer without their cancer growing. About 300 adults with stage IIIB or IV disease will receive either the combination or osimertin…

This study tests a combination of two targeted drugs (defactinib and avutometinib) plus an immunotherapy (nivolumab) in 50 adults with advanced LKB1-mutant lung adenocarcinoma that no longer responds to standard anti-PD1 treatment. The goal is to see if this triple therapy can sh…

This study tests a special dye that attaches to lung cancer cells and makes them glow under a camera during surgery. The goal is to help surgeons see and remove all cancer tissue more accurately. About 30 adults with lung cancer or lung metastases will receive the dye before thei…

This study tests whether giving radiation in three smaller doses (fractionated SRS) works better than the standard single large dose (SRS) for people whose cancer has spread to the brain. About 269 adults with certain cancers (lung, breast, melanoma, kidney, or gastrointestinal) …

This study looks at whether updating radiation treatment plans at set times during therapy can lower side effects for people with non-small cell lung cancer. As tumors shrink from radiation, healthy tissue can get exposed, so researchers want to see if planned re-designs help. Ab…

This early-stage study tests whether giving palliative radiotherapy together with the drug lurbinectedin is safe for people with extensive-stage small cell lung cancer that has spread beyond the chest. About 22 adults whose cancer worsened after initial chemotherapy will receive …

This study tests whether a special yoga program can improve physical function, fatigue, sleep, and quality of life for people with lung or esophageal cancer who are getting radiation therapy, and also for their family caregivers. About 400 patient-caregiver pairs will take part. …

This study looks at how PET/CT scans change during chemoimmunotherapy and radiation therapy in people with stage IV non-small cell lung cancer. Researchers want to see if these scan changes can help predict how well the cancer responds to treatment. About 80 participants who have…